ホーム>>Signaling Pathways>> GPCR/G protein>> Cannabinoid Receptor>>AZD1940

AZD1940

カタログ番号GC62855

AZD1940 は、ヒト CB1R および CB2R に対してそれぞれ 7.93 および 9.06 の pKi 値を持つ、経口活性の高親和性カンナビノイド CB1/CB2 受容体アゴニストです。

Products are for research use only. Not for human use. We do not sell to patients.

AZD1940 化学構造

Cas No.: 881413-29-2

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$396.00
在庫あり
1mg
$144.00
在庫あり
5mg
$360.00
在庫あり
10mg
$612.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

AZD1940 is an orally active, high affinity cannabinoid CB1/CB2 receptor agonist with pKi values of 7.93 and 9.06 for human CB1R and CB2R, respectively. AZD1940 shows a robust analgesia action[1][2].

AZD1940 binds with high affinity to human, rat and mouse CB1 and CB2 receptors and displays full agonism at both receptors in all three species[1][2].

When given orally to rats, AZD1940 produces a robust analgesia in different models of inflammatory and neuropathic pain[1][2].For AZD1940, low brain uptake at analgesic doses has been demonstrated in both rats and primates[1].

[1]. Jarkko KalliomÄki, et al. Evaluation of the analgesic efficacy and psychoactive effects of AZD1940, a novel peripherally acting cannabinoid agonist, in human capsaicin-induced pain and hyperalgesia. Clin Exp Pharmacol Physiol. 2013 Mar;40(3):212-8.
[2]. Magnus Schou, et al. Radiolabeling of the cannabinoid receptor agonist AZD1940 with carbon-11 and PET microdosing in non-human primate. Nucl Med Biol. 2013 Apr;40(3):410-4.

レビュー

Review for AZD1940

Average Rating: 5 ★★★★★ (Based on Reviews and 27 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AZD1940

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.